2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

4:30PM-6:00PM: Abstract Number: 1092

Illicit Drug Use in US Adults with Chronic Low Back Pain: Nhanes 2009-2010

ACR/ARHP Combined Abstract Session: Rehabilitation

4:30PM-6:00PM: Abstract Number: 1034

Immunomodulation By a Second-Generation Peptidyl Arginine Deiminase Inhibitor Abrogates Collagen-Induced Arthritis in a Therapeutic Protocol

Rheumatoid Arthritis - Animal Models I

4:30PM-6:00PM: Abstract Number: 1011

Impact of a Musculoskeletal “Mini-Residency” Continuing Professional Education Program on Knee MRI Orders By Primary Care Providers

Education

4:30PM-6:00PM: Abstract Number: 1037

Impaired Regulatory T Cell Survival in the Pathogenesis of Autoreactive Arthritis Mediated By CD11c-Deletion of Flip

Rheumatoid Arthritis - Animal Models I

4:30PM-6:00PM: Abstract Number: 1036

Important Role of microRNA-146a in Inflammatory Arthritis By Controlling Local Bone Destruction

Rheumatoid Arthritis - Animal Models I

4:30PM-6:00PM: Abstract Number: 1084

Improved Survival in Granulomatosis with Polyangiitis: A General Population-Based Study

Vasculitis I

4:30PM-6:00PM: Abstract Number: 1014

Improvement in Mentoring Associated with Implementation of an Inter-Institutional Mentoring Program within Pediatric Rheumatology

Education

4:30PM-6:00PM: Abstract Number: 1029

Improving Gout Outcomes Using a Disease Management Program within an Integrated Health System

Quality Measures and Quality of Care

4:30PM-6:00PM: Abstract Number: 1028

Improving Pneumococcal Immunization Rates Among Immunocompromised Adolescent Patients at a Tertiary Care Children’s Hospital

Quality Measures and Quality of Care

4:30PM-6:00PM: Abstract Number: 1006

Incident Frequent Knee Pain Is Associated with Changes in Semi-Quantitative Imaging Biomarkers of Inflammation

Osteoarthritis - Clinical Aspects I: Imaging and Epidemiology

4:30PM-6:00PM: Abstract Number: 1059

Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

4:30PM-6:00PM: Abstract Number: 1025

Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI): Genotype-Phenotype Correlation

Pediatric Rheumatology - Pathogenesis and Genetic

4:30PM-6:00PM: Abstract Number: 1085

Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis

Vasculitis I

4:30PM-6:00PM: Abstract Number: 1044

Many Patients with Early Rheumatoid Arthritis Want Triple Therapy: An Analysis Combining Comparative Effectiveness Research and Patients Preferences to Inform Treatment Recommendations

Rheumatoid Arthritis - Clinical Aspects I - Treatment Advances and Strategies

4:30PM-6:00PM: Abstract Number: 1041

Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis

Rheumatoid Arthritis - Clinical Aspects I - Treatment Advances and Strategies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].